We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Model in Evaluating Clinical, Psychosocial, and Health Economic Factors in Adolescent and Young Adult Patients With Cancer

This study is currently recruiting participants.
Verified August 2017 by University of Southern California
Sponsor:
ClinicalTrials.gov Identifier:
NCT03057639
First Posted: February 20, 2017
Last Update Posted: August 22, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
University of Southern California
  Purpose
This research trial studies the Adolescent and Young Adult (AYA) Cancers Clinical Model in evaluating clinical, psychosocial, and health economic factors in adolescent and young adult patients with cancer. Studying the Adolescent and Young Adult Cancers Clinical Model may help doctors learn more about the effect of the AYA services on patient care, including clinical (nurse navigation), psychosocial (social work), and economic (financial) areas.

Condition Intervention
Malignant Neoplasm Other: Quality-of-Life Assessment Other: Questionnaire Administration

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Adolescent and Young Adult (AYA) Cancers Clinical Model: An Evaluation of the AYA Clinical Care Model by Assessment of Clinical, Psychosocial, and Health Economic Factors Related to AYA Patient Outcomes

Resource links provided by NLM:


Further study details as provided by University of Southern California:

Primary Outcome Measures:
  • Clinical care model impact on patient access to AYA specific supportive care as assessed by questionnaires (Norris) [ Time Frame: Up to 2 years ]
    Questionnaire scores will be expressed as median values with 95% confidence intervals.

  • Clinical care model impact on patient's/health care professional's satisfaction with the AYA at USC program as assessed by questionnaires (LAC+USC) [ Time Frame: Up to 2 years ]
    Questionnaire scores will be expressed as median values with 95% confidence intervals.

  • Cost of care (Norris) [ Time Frame: Up to 2 years ]
    Direct health care costs analyses will be performed from the Total Costs of Care payer perspective. Direct cost will be estimated from paid claims in the extracted electronic medical records, which will include costs for all health care utilization such as outpatient, procedures, laboratory, emergency room visits, hospitalization, and pharmacy. As the healthcare utilization and costs will likely be extremely skewed, healthcare utilization and cost measures will be estimated by using an econometric model (e.g., a negative binomial regression model for utilization count data [number of services

  • Incremental cost (Norris) [ Time Frame: Up to 2 years ]
    The incremental cost between AYA enrolled and non-enrolled will be calculated. In addition to estimation the magnitude of the variability attributed to the different sources of variation, we will also generate an influence diagram (also known as tornado diagram) to display which variables exert the most influence on cost driver.

  • Processes that can be improved (Norris) [ Time Frame: Up to 2 years ]
    Will utilize the prospective data to estimate key aspects of the AYA at USC service. Any variances in the services over time will be utilized to improve quality and reliability care delivery.


Secondary Outcome Measures:
  • Care coordination as assessed by the mean number of supportive care referrals, telephone or email encounters for additional information, educational materials, and or additional interventions provided by the nurse navigator and/or social worker (LAC+USC) [ Time Frame: Up to 2 years ]
    Will be measured using an implementation guide.

  • Patient continuity of care as assessed by the mean number of visits per patient with the assigned clinic lead physician (LAC+USC) [ Time Frame: Up to 2 years ]
    Will be measured using an implementation guide.

  • Resource allocation as assessed by the mean number of supportive care referrals and per patient follow-up conducted by the nurse navigator and/or social worker (LAC+USC) [ Time Frame: Up to 2 years ]
    Will be measured using an implementation guide.

  • Satisfaction of health care staff as assessed by questionnaires (LAC+USC) [ Time Frame: Up to 2 years ]
    Questionnaire scores will be expressed as median values with 95% confidence intervals.

  • Satisfaction of services as assessed by questionnaires (LAC+USC) [ Time Frame: Up to 2 years ]
    Questionnaire scores will be expressed as median values with 95% confidence intervals.


Estimated Enrollment: 850
Actual Study Start Date: February 3, 2017
Estimated Study Completion Date: February 3, 2020
Estimated Primary Completion Date: August 3, 2019 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Observational (questionnaires)
Patients complete questionnaires at referral, week 4-8, week 10-12, and at the completion of systemic therapy.
Other: Quality-of-Life Assessment
Ancillary studies
Other Name: Quality of Life Assessment
Other: Questionnaire Administration
Ancillary studies

Detailed Description:

PRIMARY OBJECTIVES:

I. To provide economic understanding of the AYA at University of Southern California (USC) model of care. (Norris)

II. To evaluate the existing AYA at USC program to determine the direct and indirect impact on cost of care. (Norris)

III. To utilize the results of objective (i) to identify cost effectiveness and efficiencies to patient and institution. (Norris)

IV. To identify specific processes within our model of care that can be improved. (Norris)

V. To improve healthcare access to AYA-specific cancer care for patients ages 15-39 served by the Los Angeles County (LAC)+USC oncology pilot clinics. (LAC+USC)

VI. To improve the psychosocial outcome of AYA-specific cancer care patients. (LAC+USC)

VII. To provide AYA specific elements of care routinely and proactively to AYA cancer patients. (LAC+USC)

VIII. To improve care quality through patient satisfaction. (LAC+USC)

IX. To improve resource utilization and care coordination through improved patient navigation through efficiency and patient navigation. (LAC+USC)

OUTLINE:

Patients complete questionnaires at referral, week 4-8, week 10-12, and at the completion of systemic therapy.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   15 Years to 39 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Adolescent and Young Adult (AYA) with cancer who are being seen at the USC/Norris Cancer Center and at LAC+USC Medical Center.
Criteria

Inclusion Criteria:

  • Patients diagnosed with cancer
  • ADDITIONAL GRANT SPECIFIC INCLUSION CRITERIA - UNIHEALTH (NORRIS):
  • Patients who were diagnosed at USC Norris Comprehensive Cancer Center and Hospital
  • Patients who are currently receiving treatment for a primary or secondary tumor at USC Norris Comprehensive Cancer Center and Hospital
  • ADDITIONAL GRANT SPECIFIC INCLUSION CRITERIA - QUEENSCARE (LAC + USC):
  • Patients who are being seen in sarcoma, gynecologic oncology, or genitourinary clinic at LAC + USC (clinics A2C or 4P1)
  • Patients who are currently receiving treatment for a primary or secondary tumor at LAC + USC and who receive oncology care from one of the clinics above
  • Patients who are at or below the poverty level

Exclusion Criteria:

  • Inability to sign informed assent and/or consent
  • Patients who are not receiving chemotherapy and/or radiation therapy for a primary or secondary tumor
  • Primary oncology treatment team believes that participation in AYA at USC would not benefit their patient
  • ADDITIONAL GRANT SPECIFIC EXCLUSION CRITERIA - UNIHEALTH (NORRIS):
  • Patients who are not receiving treatment for a primary or secondary tumor at USC Norris Comprehensive Cancer Center and Hospital
  • ADDITIONAL GRANT SPECIFIC EXCLUSION CRITERIA - QUEENSCARE (LAC+USC):
  • Patients who are not receiving oncology care for a primary or secondary tumor in sarcoma, gynecologic oncology, or genitourinary clinic at LAC + USC (clinics A2C or 4P1)
  • Patients who are above the poverty level
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03057639


Contacts
Contact: Terry Church 323-865-3000 Terry.Church@med.usc.edu

Locations
United States, California
USC / Norris Comprehensive Cancer Center Recruiting
Los Angeles, California, United States, 90033
Contact: James S. Hu    323-865-3900    james.hu@med.usc.edu   
Principal Investigator: James S. Hu         
Sponsors and Collaborators
University of Southern California
National Cancer Institute (NCI)
Investigators
Principal Investigator: James Hu, MD University of Southern California
  More Information

Responsible Party: University of Southern California
ClinicalTrials.gov Identifier: NCT03057639     History of Changes
Other Study ID Numbers: 0S-16-6
NCI-2017-00210 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
0S-16-6 ( Other Identifier: USC / Norris Comprehensive Cancer Center )
P30CA014089 ( U.S. NIH Grant/Contract )
First Submitted: February 15, 2017
First Posted: February 20, 2017
Last Update Posted: August 22, 2017
Last Verified: August 2017

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Neoplasms